Docking, Synthesis, and In vitro Anti-depressant Activity of Certain Isatin Derivatives


Cite item

Full Text

Abstract

Background:In vitro, the molecular docking method has been suggested for estimating the biological affinity of the pharmacophores with physiologically active compounds. It is the latter stage in molecular docking, and the docking scores are examined using the AutoDock 4.2 tool program. The chosen compounds can be evaluated for in vitro activity based on the binding scores, and the IC50 values can be computed.

Objective:The purpose of this work was to create methyl isatin compounds as potential antidepressants, compute physicochemical characteristics, and carry out docking analysis.

Methods:The protein data bank of the RCSB (Research Collaboratory for Structural Bioinformatics) was used to download the PDB structures of monoamine oxidase (PDB ID: 2BXR) and indoleamine 2,3-dioxygenase (PDB ID: 6E35). Based on the literature, methyl isatin derivatives were chosen as the lead chemicals. By determining their IC50 values, the chosen compounds were tested for in vitro anti-depressant activity.

Results:The binding scores for the interactions of SDI 1 and SD 2 with indoleamine 2,3 dioxygenase were found to be -10.55 kcal/mol and -11.08 kcal/mol, respectively, while the scores for their interactions with monoamine oxidase were found to be -8.76 kcal/mol and -9.28 kcal/mol, respectively, using AutoDock 4.2. The relationship between biological affinity and pharmacophore electrical structure was examined using the docking technique. The chosen compounds were tested for their ability to inhibit MAO, and the IC50 values for each were found to be 51.20 and 56, respectively.

Conclusion:This investigation has identified many novel and effective MAO-A inhibitors from the family of chemicals known as methyl isatin derivatives. Lead optimization was applied to the SDI 1 and SDI 2 derivatives. The superior bioactivity, pharmacokinetic profile, BBB penetration, pre-ADMET profiles, such as HIA (human intestinal absorption) and MDCK (Madin-Darby canine kidney), plasma protein binding, toxicity assessment, and docking outcomes, have been obtained. According to the study, synthesised isatin 1 and SDI 2 derivatives exhibited a stronger MAO inhibitory activity and effective binding energy, which may help prevent stress-induced depression and other neurodegenerative disorders caused by a monoamine imbalance.

About the authors

Thulasingam Muthukumaran

Department of Pharmacology, College of Pharmaceutical Sciences, Dayananda Sagar University

Email: info@benthamscience.net

Asok K

Department of Pharmacology, College of Pharmacy,, Sri Ramakrishna Institute of Paramedical Sciences,

Author for correspondence.
Email: info@benthamscience.net

Francis M Saleshier

Department of Pharmaceutical Chemistry, College of Pharmacy, Sri Ramakrishna Institute of Paramedical Sciences

Email: info@benthamscience.net

References

  1. Institute of health metrics and evaluation. Global health data exchange (GHDx). Available from: http://ghdx.healthdata.org/gbd-res ults-tool?params=gbd-api-2019-permalink/d780dffbe8a381b25e1416884959e88b (Accessed on: 1 May 2021).
  2. World health organization. Depression. 2020. Available from: https://www.who.int/news-room/fact-sheets/detail/depression (Accessed on: 11th December 2020).
  3. Liao, D.; Lev, C.; Cao, L.; Yao, D.; Wu, Y.; Long, M.; Liu, N.; Jiang, P. Curcumin attenuates chronic unpredictable mild stress-induced depressive-like behaviours via restoring changes in oxidative stress and the activation of Nrf2 signaling pathway in rats. Oxid. Med. Cell. Longev., 2020, 2022, 9268083.
  4. James, N.D. Drug therapy for depression and anxiety disorder. In: Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 12 th ed; Laurence, L.B.; John, S.L.; Keith, L.P., Eds.; McGraw-Hill Publication: New York, 2006; pp. 397-416.
  5. Deweshri, R.; Pramod, K. Indole derivatives acting on central nervous system. Pharm Sci Bioscientific Res., 2016, 6(1), 144-156.
  6. Vandana, K.; Akash, M. A review on isatin derivatives with diverse biological activities. World J. Pharm. Res., 2017, 6(16), 318-332.
  7. Dias, R.; de Azevedo, W., Jr. Molecular docking algorithms. Curr. Drug Targets, 2008, 9(12), 1040-1047. doi: 10.2174/138945008786949432 PMID: 19128213
  8. Alexander, H.; Rolf, H. Modern Methods of Drug Discovery; Spinger, private limited: New Delhi, India, 2009, pp. 207-230.
  9. Noël, F.; Nascimento-Viana, J.B.; Romeiro, L.A.S.; Silva, R.O.; Lemes, L.F.N.; Oliveira, A.S.; Giorno, T.B.S.; Fernandes, P.D.; Silva, C.L.M. ADME studies and preliminary safety pharmacology of LDT5, a lead compound for the treatment of benign prostatic hyperplasia. Braz. J. Med. Biol. Res., 2016, 49(12), e5542. doi: 10.1590/1414-431x20165542 PMID: 27901175
  10. Sliwoski, G.; Kothiwale, S.; Meiler, J.; Lowe, E.W., Jr. Computational methods in drug discovery. Pharmacol. Rev., 2014, 66(1), 334-395. doi: 10.1124/pr.112.007336 PMID: 24381236
  11. Lipinski, C.A. Lead- and drug-like compounds: The rule-of-five revolution. Drug Discov. Today. Technol., 2004, 1(4), 337-341. doi: 10.1016/j.ddtec.2004.11.007 PMID: 24981612
  12. Dhiman, P.; Malik, N.; Khatkar, A. Natural based piperine derivatives as potent monoamine oxidase inhibitors: An in silico ADMET analysis and molecular docking studies. BMC Chem., 2020, 14(1), 12. doi: 10.1186/s13065-020-0661-0 PMID: 32099971
  13. Kuppusamy, A.; Arumugam, M.; George, S. Combining in silico and in vitro approaches to evaluate the acetylcholinesterase inhibitory profile of some commercially available flavonoids in the management of alzheimer’s disease. Int. J. Biol. Macromol., 2017, 95, 199-203. doi: 10.1016/j.ijbiomac.2016.11.062 PMID: 27871793
  14. Manley-King, C.I.; Bergh, J.J.; Petzer, J.P. Inhibition of monoamine oxidase by selected C5- and C6-substituted isatin analogues. Bioorg. Med. Chem., 2011, 19(1), 261-274. doi: 10.1016/j.bmc.2010.11.028 PMID: 21134756
  15. Grewal, A.S. Isatin derivatives with several biological activities. Inter. J. Pharm. Res., 2014, 6(1), 1-7.
  16. Nerella, R.; Lingala, S.; Manda, S. Synthesis and CNS activity of new indole derivatives. Int. J. Pharm. Sci. Rev. Res., 2011, 7, 9-13.
  17. Medvedev, A.E. Ivanor. Introduction of indole derivatives with MAO-A and MAO-B studies on the structure inhibitory activity relationship. Biochem. Int., 1995, 36, 133.
  18. Porsolt, R.D.; Anton, G.; Blavet, N.; Jalfre, M. Behavioural despair in rats: A new model sensitive to antidepressant treatments. Eur. J. Pharmacol., 1978, 47(4), 379-391. doi: 10.1016/0014-2999(78)90118-8 PMID: 204499
  19. Kandagalla, S.; Sharath, B.S.; Bharath, B.R.; hani, U.; Manjunatha, H. Molecular docking analysis of curcumin analogues against kinase domain of ALK5. In Silico Pharmacol., 2017, 5(1), 15. doi: 10.1007/s40203-017-0034-0 PMID: 29308351
  20. Khan, M.F.; Nahar, N.; Rashid, R.B.; Chowdhury, A.; Rashid, M.A. Computational investigations of physicochemical, pharmacokinetic, toxicological properties and molecular docking of betulinic acid, A constituent of Corypha taliera (Roxb.) with phospholipase A2 (PLA2). BMC Complement. Altern. Med., 2018, 18(1), 48. doi: 10.1186/s12906-018-2116-x PMID: 29391000
  21. Yasser, A.; Hussein, G.; Eman, N. Assessment of the antidepressant effect of caffeine using rat model of depression induced by reserpine. Bull. Natl. Res. Cent., 2018, 42(36), 1-9.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers